The Grantee invites submission of qualifications and proposal data (collectively referred to as the “Proposal”) from interested U.S. firms that are qualified on the basis of experience and capability to execute a feasibility study (“Study”) for the AMATA Corporation (“AMATA” or “Grantee”) that would support the development of a regional oncology center in Amata City, Chonburi Province, Thailand. (the “Project”). The Proposal submission deadline is October 21, 2022 at 5 p.m. EDT. The U.S. firm selected will be paid in U.S. dollars from a $589,110 grant to AMATA from the U.S. Trade and Development Agency.
About the Grantee:
AMATA Corporation is a world-leading industrial developer headquartered in Bangkok, Thailand. Established in 1989, AMATA specializes in planning, developing, managing, and marketing integrated industrial estates. The company operates in the following three segments: industrial estate development; utility services; and commercial rental (see additional information on healthcare experience below). AMATA has a longstanding practice of working with U.S. firms and has built a large customer base of Fortune 500 companies including PepsiCo, Cardinal Health, and other global corporations. The company has a strong regional platform, which has expanded to serve a growing number of global clientele, with over 1,400 customers. Within Thailand, AMATA manages two mega-industrial estates: AMATA City Chonburi and AMATA City Rayong. AMATA has experience in health developments through a joint-venture hospital with Vibharam Hospital Co. established in 2005 at Amata City Chonburi, which has transformed into a highly successful and profitable investment. The Vibharam AMATA Nakorn Hospital is a nine story, 141-bed facility that provides a range of treatment services, including pediatrics, obstetrics, and orthopedics.
The Study will build upon a previously funded pre-feasibility assessment by IQVIA, which assumed a 10-year implementation plan and medical tourism-based demand, by analyzing potential ways to shorten the Project timeline and evaluate growing domestic cancer treatment demand. For example, the Study will provide a more in-depth analysis of the number of inpatient beds needed, based on a range of domestic and/or medical tourism demand scenarios. The proposed oncology center would likely offer all three modalities of modern cancer treatment, which can often be conducted on an outpatient basis: (i) surgical oncology (removal of the tumors); (ii) radiation oncology (use of radiation therapy to treat tumors); and (iii) medical oncology (use of chemotherapy to treat tumors or blood cancers). The Study will provide AMATA the analysis needed to forecast the appropriate number of inpatient beds for the Project.
The oncology center is expected to be part of a larger medical complex that AMATA is developing in collaboration with Mahidol University and the Thailand Center of Excellence for Life Sciences (“TCELS”). The oncology center would be the first stage of that development, entitled “Meditown.” The Meditown development is part of AMATA’s broader plan to provide world class medical services and to collaborate with industry leaders in pharmaceuticals, medical equipment, and research, with a focus on international cooperation. In October 2020, partners AMATA, Mahidol University, and TCELS signed a joint Memorandum of Understanding (“MOU”) to formalize support for Meditown. AMATA is currently waiting for the Thai Government’s approval for Meditown to secure the designation of a project of national significance, which will help AMATA obtain special investment status and other regulatory approval incentives. AMATA and its partners hope to formally receive that distinction during the course of the Study.
About the Study:
Overall, this effort will prepare a comprehensive market assessment and master planning document for the development of a regional oncology center. The Study would support the Project by providing the necessary data and analysis for phased implementation of a new oncology center that would help to better meet the gap in cancer care treatment needs in Thailand and the region. The planning would include things such as architectural designs, an equipment list, cost estimates, staffing plan, commissioning and operating plan, U.S. sources of supply, financial analyses, etc. Furthermore, the Study would develop an “Investment Business Plan” to help initiate discussions between AMATA and prospective U.S. cancer center/health system partner(s). The nature of any such relationship with the potential U.S. partner(s) is still to be determined but would likely include some mix of consulting services, hospital management, and financing. The Study will take approximately 4 months to complete. Once financing is obtained, it typically takes about 3 years to design and construct a 150 to 200 bed hospital. Detailed estimates and timelines will be developed further throughout the course of the analysis.